Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Burning Rock Biotech Limited stock logo
BNR
Burning Rock Biotech
$2.92
+1.0%
$4.43
$2.62
$8.99
$29.91M0.6715,775 shs13,708 shs
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
$0.33
-14.8%
$0.40
$0.25
$1.28
$17.03M1.19163,406 shs4.12 million shs
OpGen, Inc. stock logo
OPGN
OpGen
$4.98
-0.2%
$2.96
$0.53
$5.30
$41.61M-1.6110,215 shs23,483 shs
P3 Health Partners Inc. stock logo
PIII
P3 Health Partners
$8.99
+2.7%
$8.96
$7.00
$40.50
$64.57M0.9620,326 shs3,388 shs
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Burning Rock Biotech Limited stock logo
BNR
Burning Rock Biotech
+1.04%-0.68%-32.78%-56.93%-61.33%
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
0.00%0.00%-9.97%-45.65%-69.05%
OpGen, Inc. stock logo
OPGN
OpGen
-0.20%+1.63%+25.44%+357.22%+23.57%
P3 Health Partners Inc. stock logo
PIII
P3 Health Partners
+2.74%+1.12%+9.57%+2.74%-66.53%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Burning Rock Biotech Limited stock logo
BNR
Burning Rock Biotech
1.8608 of 5 stars
0.05.00.00.03.61.70.6
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
0.5442 of 5 stars
0.03.01.70.00.00.80.6
OpGen, Inc. stock logo
OPGN
OpGen
N/AN/AN/AN/AN/AN/AN/AN/A
P3 Health Partners Inc. stock logo
PIII
P3 Health Partners
2.6206 of 5 stars
3.34.00.00.03.40.80.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Burning Rock Biotech Limited stock logo
BNR
Burning Rock Biotech
0.00
N/AN/AN/A
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
0.00
N/AN/AN/A
OpGen, Inc. stock logo
OPGN
OpGen
0.00
N/AN/AN/A
P3 Health Partners Inc. stock logo
PIII
P3 Health Partners
2.50
Moderate Buy$16.2580.76% Upside

Current Analyst Ratings Breakdown

Latest ENZ, PIII, OPGN, and BNR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/21/2025
P3 Health Partners Inc. stock logo
PIII
P3 Health Partners
Lake Street Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$50.00 ➝ $20.00
(Data available from 5/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Burning Rock Biotech Limited stock logo
BNR
Burning Rock Biotech
$515.82M0.06N/AN/A$10.56 per share0.28
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
$29.09M0.59N/AN/A$1.09 per share0.30
OpGen, Inc. stock logo
OPGN
OpGen
$2.67M15.57N/AN/A($11.55) per share-0.43
P3 Health Partners Inc. stock logo
PIII
P3 Health Partners
$1.50B0.04$3.88 per share2.32$0.45 per share19.98
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Burning Rock Biotech Limited stock logo
BNR
Burning Rock Biotech
-$92.07M-$1.88N/AN/A-83.50%-60.68%-42.30%5/26/2025 (Estimated)
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
-$26.08MN/A0.00N/A-75.34%-7.96%-5.49%6/12/2025 (Estimated)
OpGen, Inc. stock logo
OPGN
OpGen
-$32.67MN/A0.00N/A-1,140.36%N/A-287.58%6/2/2025 (Estimated)
P3 Health Partners Inc. stock logo
PIII
P3 Health Partners
-$57.77M-$49.00N/AN/AN/A-6.95%-71.31%-11.93%5/6/2025 (Estimated)

Latest ENZ, PIII, OPGN, and BNR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
P3 Health Partners Inc. stock logo
PIII
P3 Health Partners
-$5.00N/AN/AN/A$362.09 millionN/A
3/27/2025Q4 2024
P3 Health Partners Inc. stock logo
PIII
P3 Health Partners
-$8.50-$16.00-$7.50-$0.36$378.88 million$370.69 million
3/25/2025Q4 2024
Burning Rock Biotech Limited stock logo
BNR
Burning Rock Biotech
-$1.3970-$1.08+$0.3170-$1.08N/A$17.27 million
3/17/2025Q2 2025
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
N/A-$0.02N/A-$0.03N/A$7.33 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Burning Rock Biotech Limited stock logo
BNR
Burning Rock Biotech
N/AN/AN/AN/AN/A
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
$0.40123.08%N/AN/AN/A
OpGen, Inc. stock logo
OPGN
OpGen
N/AN/AN/AN/AN/A
P3 Health Partners Inc. stock logo
PIII
P3 Health Partners
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Burning Rock Biotech Limited stock logo
BNR
Burning Rock Biotech
N/A
3.04
2.78
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
N/A
2.55
2.28
OpGen, Inc. stock logo
OPGN
OpGen
N/A
5.45
5.45
P3 Health Partners Inc. stock logo
PIII
P3 Health Partners
1.11
0.53
0.53

Institutional Ownership

CompanyInstitutional Ownership
Burning Rock Biotech Limited stock logo
BNR
Burning Rock Biotech
30.03%
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
36.90%
OpGen, Inc. stock logo
OPGN
OpGen
2.68%
P3 Health Partners Inc. stock logo
PIII
P3 Health Partners
7.75%

Insider Ownership

CompanyInsider Ownership
Burning Rock Biotech Limited stock logo
BNR
Burning Rock Biotech
30.30%
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
11.40%
OpGen, Inc. stock logo
OPGN
OpGen
43.80%
P3 Health Partners Inc. stock logo
PIII
P3 Health Partners
15.76%
CompanyEmployeesShares OutstandingFree FloatOptionable
Burning Rock Biotech Limited stock logo
BNR
Burning Rock Biotech
1,39010.24 million7.14 millionNot Optionable
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
52052.40 million46.29 millionOptionable
OpGen, Inc. stock logo
OPGN
OpGen
1008.36 million4.70 millionNot Optionable
P3 Health Partners Inc. stock logo
PIII
P3 Health Partners
5007.18 million294.74 millionNot Optionable

Recent News About These Companies

P3 Health Partners Inc trading halted, news pending
P3 Health Partners (PIII) Gets a Hold from TD Cowen

New MarketBeat Followers Over Time

Media Sentiment Over Time

Burning Rock Biotech stock logo

Burning Rock Biotech NASDAQ:BNR

$2.92 +0.03 (+1.04%)
As of 04/30/2025 03:57 PM Eastern

Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoCompass IO, a corresponding test for liquid biopsy samples; OncoScreen IO, a pan-cancer test for tissue samples; and OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC. In addition, the company provides ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and brPROPHET, a pre-operative ctDNA detection and post-operative MRD calling for relapsed patients. Further, it has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; licensing agreement with Oncocyte Corporation to in-license DetermaRx, a risk stratification test for early stage lung cancer patients in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, and IMPACT Therapeutics and Merck KGaA. Additionally, the company offers OncoMaster, an automatic NGS data analysis and report interpretation machine for in-hospital model. Burning Rock Biotech Limited was incorporated in 2014 and is headquartered in Guangzhou, China.

Enzo Biochem stock logo

Enzo Biochem NYSE:ENZ

$0.32 -0.06 (-14.83%)
Closing price 04/17/2025
Extended Trading
$0.32 0.00 (0.00%)
As of 04/17/2025 05:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Enzo Biochem, Inc. develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. It also provides AMPIVIEW in situ hybridization probes for enhanced detection of low expressed targets useful in the growing spatial biology space; reagents and assays for cell and gene therapy research and development; POLYVIEW PLUS Enhanced Immunohistochemistry platform, offers solutions within the area of anatomical pathology through optimized assays; Enhanced Immunoassays, pushing sensitivity to expand immunoassay applications for basic research, bioprocess, and diagnostics; AMPIPROBE, a nucleic acid amplification platform; and Axxora.com, a proven distribution platform for original manufacturers of innovative research reagents. The company's proprietary products and technologies in translational research and drug development areas, including cell biology, genomics, assays, immunohistochemistry, and small molecule chemistry. It markets its products and services through its direct sales force and a network of distributors. The company was incorporated in 1976 and is headquartered in Farmingdale, New York.

OpGen stock logo

OpGen NASDAQ:OPGN

$4.98 -0.01 (-0.20%)
As of 04/30/2025 01:59 PM Eastern

OpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The company's products also comprise ARES Technology Platform, including ARES reference database on antimicrobial resistance using next generation sequencing technology and artificial intelligence powered bioinformatics solutions for antibiotic response prediction; and Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers. It also utilizes molecular diagnostics and informatics to help combat infectious diseases. The company helps clinicians with information about life threatening infections to enhance patient outcomes, and to decrease the spread of infections caused by multidrug-resistant microorganisms. OpGen, Inc. has a collaboration with the New York State Department of Health and ILÚM Health Solutions, LLC to develop a research program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Rockville, Maryland.

P3 Health Partners stock logo

P3 Health Partners NASDAQ:PIII

$8.99 +0.24 (+2.74%)
As of 04/30/2025 04:00 PM Eastern

P3 Health Partners Inc., a patient-centered and physician-led population health management company, provides superior care services in the United States. It operates clinics and wellness centers. P3 Health Partners Inc. was founded in 2020 and is based in Henderson, Nevada.